share_log

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90

罗斯资本维持对Ligand Pharmicals的买入,将目标价提高至90美元
Benzinga Real-time News ·  2022/12/23 07:44

Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $85 to $90.

Roth Capital分析师斯科特·亨利维持纳斯达克(Ligand PharmPharmticals)的买入,并将目标价从85美元上调至90美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发